Home >> Chemicals Listing >> hot product list by 1  

1H-Purine-2,6-dione,3,7-dihydro-3-methyl-1-(5-oxohexyl)-7-propyl- (55242-55-2)

Identification
Name:1H-Purine-2,6-dione,3,7-dihydro-3-methyl-1-(5-oxohexyl)-7-propyl-
Synonyms:1-(5-Oxohexyl)-3-methyl-7-propylxanthine;3,7-Dihydro-3-methyl-1-(5-oxohexyl)-7-propyl-1H-purine-2,6-dione;3-Methyl-1-(5-oxohexyl)-7-propylxanthine;Albert 285;HOE 285;HWA 285;Hextol;Karsivan;Propentofylline;Propentophylline;albert-285;
CAS:55242-55-2
Molecular Formula: C15H22N4O3
Molecular Weight: 306.36
InChI: InChI=1/C15H22N4O3/c1-4-8-18-10-16-13-12(18)14(21)19(15(22)17(13)3)9-6-5-7-11(2)20/h10H,4-9H2,1-3H3
Molecular Structure: (C15H22N4O3) 1-(5-Oxohexyl)-3-methyl-7-propylxanthine;3,7-Dihydro-3-methyl-1-(5-oxohexyl)-7-propyl-1H-purine-2,6-...
Properties
Density:1.25 g/cm3
Refractive index:1.602
Appearance:Off-White Solid
Specification:

The cas register number of Propentofylline is 55242-55-2. It also can be called as 3-Methyl-1-(5-oxohexyl)-7-propylpurine-2,6-dione and the IUPAC Name about this chemical is 3-methyl-1-(5-oxohexyl)-7-propylpurine-2,6-dione. It belongs to the following product categories, such as All Inhibitors, Inhibitors, Intermediates & Fine Chemicals, Pharmaceuticals and so on. This chemical is harmful by inhalation, in contact with skin and if swallowed.

Physical properties about Propentofylline are: (1)ACD/LogP: 1.38; (2)ACD/LogD (pH 5.5): 1.38; (3)ACD/LogD (pH 7.4): 1.38; (4)ACD/BCF (pH 5.5): 6.64; (5)ACD/BCF (pH 7.4): 6.64; (6)ACD/KOC (pH 5.5): 134.9; (7)ACD/KOC (pH 7.4): 134.9; (8)#H bond acceptors: 7; (9)#Freely Rotating Bonds: 7; (10)Polar Surface Area: 75.51Å2; (11)Index of Refraction: 1.602; (12)Molar Refractivity: 83.49 cm3; (13)Molar Volume: 243.4 cm3; (14)Polarizability: 33.1x10-24cm3; (15)Surface Tension: 47.9 dyne/cm; (16)Enthalpy of Vaporization: 81.93 kJ/mol; (17)Boiling Point: 541.4 °C at 760 mmHg; (18)Vapour Pressure: 8.71E-12 mmHg at 25°C.

Propentofylline is a phosphodiesterase inhibitor and it acts as an adenosine reuptake inhibitor. This chemical can be used as a possible treatment for Alzheimer's disease and multi-infarct dementia and it can be used in the treatment of ischemic stroke, due to its vasodilating properties.

You can still convert the following datas into molecular structure:
(1)SMILES: O=C2N(c1ncn(c1C(=O)N2CCCCC(=O)C)CCC)C
(2)InChI: InChI=1/C15H22N4O3/c1-4-8-18-10-16-13-12(18)14(21)19(15(22)17(13)3)9-6-5-7-11(2)20/h10H,4-9H2,1-3H3
(3)InChIKey: RBQOQRRFDPXAGN-UHFFFAOYAK
(4)Std. InChI: InChI=1S/C15H22N4O3/c1-4-8-18-10-16-13-12(18)14(21)19(15(22)17(13)3)9-6-5-7-11(2)20/h10H,4-9H2,1-3H3
(5)Std. InChIKey: RBQOQRRFDPXAGN-UHFFFAOYSA-N

The toxicity data is as follows:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
mouse LD50 intraperitoneal 346mg/kg (346mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

BEHAVIORAL: ATAXIA
Oyo Yakuri. Pharmacometrics. Vol. 31, Pg. 357, 1986.
mouse LD50 intravenous 107mg/kg (107mg/kg)   United States Patent Document. Vol. #4289776,
mouse LD50 oral 780mg/kg (780mg/kg) SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
Oyo Yakuri. Pharmacometrics. Vol. 31, Pg. 357, 1986.
mouse LD50 subcutaneous 450mg/kg (450mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: ATAXIA

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Oyo Yakuri. Pharmacometrics. Vol. 31, Pg. 357, 1986.
rabbit LD50 intravenous 89mg/kg (89mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS

BEHAVIORAL: ATAXIA
Oyo Yakuri. Pharmacometrics. Vol. 31, Pg. 357, 1986.
rabbit LD50 oral 405mg/kg (405mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS

BEHAVIORAL: ATAXIA
Oyo Yakuri. Pharmacometrics. Vol. 31, Pg. 357, 1986.
rat LD50 intraperitoneal 196mg/kg (196mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

BEHAVIORAL: ATAXIA
Oyo Yakuri. Pharmacometrics. Vol. 31, Pg. 357, 1986.
rat LD50 intravenous 180mg/kg (180mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

BEHAVIORAL: ATAXIA
Oyo Yakuri. Pharmacometrics. Vol. 31, Pg. 357, 1986.
rat LD50 oral 940mg/kg (940mg/kg) SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
Oyo Yakuri. Pharmacometrics. Vol. 31, Pg. 357, 1986.
rat LD50 subcutaneous 338mg/kg (338mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

BEHAVIORAL: ATAXIA
Oyo Yakuri. Pharmacometrics. Vol. 31, Pg. 357, 1986.

Storage Temperature: −20°C
Usage:A c-AMP phosphodiesterase inhibitor. A nerve growth factor stimulator. An adenosine transport inhibitor. A non-selective adenosine receptor antagonist. Nootropic
Safety Data
Hazard Symbols Xn: Harmful
 

Other Product